Drug Profile
Atorvastatin - Medlab
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Medlab
- Class Amides; Antihyperlipidaemics; Esters; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Hypercholesterolaemia in Australia (Buccal) (Medlab pipeline, September 2023)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Hypercholesterolaemia in Australia (Buccal, Spray)
- 21 Dec 2017 Medlab withdraws a phase 0 trial in Hypercholesterolaemia in Australia due to lack of funding and recruitment (ACTRN12615001285549)